Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

被引：118
作者：
Wang, Qiao [1 ]
Peng, Hongling [1 ]
Qi, Xiaorong [1 ]
Wu, Min [2 ]
Zhao, Xia [1 ]
机构：
[1] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, West China Hosp 2,Dept Gynecol & Obstet,Minist Ed, Dev & Related Dis Women & Children Key Lab Sichua, Chengdu 610041, Sichuan, Peoples R China
[2] Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND 58203 USA
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2020年 / 5卷 / 01期
关键词：
PHASE-II TRIAL; RECURRENT EPITHELIAL OVARIAN; PLATINUM-RESISTANT OVARIAN; PRIMARY PERITONEAL CARCINOMA; ANTIBODY-DRUG CONJUGATE; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; PERSISTENT ENDOMETRIAL CANCER; MIRVETUXIMAB SORAVTANSINE IMGN853; PEGYLATED LIPOSOMAL DOXORUBICIN; SQUAMOUS-CELL-CARCINOMA;
D O I：
10.1038/s41392-020-0199-6
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment. The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies, which are emerging as groundbreaking and promising cancer treatment strategies. In gynecologic malignancies, potential therapeutic targeted agents include antiangiogenic agents, poly (ADP-ribose) polymerase (PARP) inhibitors, tumor-intrinsic signaling pathway inhibitors, selective estrogen receptor downregulators, and immune checkpoint inhibitors. In this article, we provide a comprehensive review of the clinical evidence of targeted agents in gynecological cancers and discuss the future implication.
引用
收藏
页数：34
相关论文
共 50 条
[41]   Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research [J].
Gadducci, Angiolo ;
Guerrieri, Maria Elena .
ANTICANCER RESEARCH, 2017, 37 (11) :5955-5965
[42]   Sentinel Node Mapping in Gynecologic Cancers: A Comprehensive Review [J].
Skanjeti, Andrea ;
Dhomps, Anthony ;
Paschetta, Cristina ;
Tordo, Jeremie ;
Giammarile, Francesco .
SEMINARS IN NUCLEAR MEDICINE, 2019, 49 (06) :521-533
[43]   Molecular targeted therapies for cancer: Sorafenib monotherapy and its combination with other therapies (Review) [J].
Ibrahim, Nuha ;
Yu, Yan ;
Walsh, William R. ;
Yang, Jia-Lin .
ONCOLOGY REPORTS, 2012, 27 (05) :1303-1311
[44]   Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review) [J].
Grazia, Giulia ;
Penna, Ilaria ;
Perotti, Valentina ;
Anichini, Andrea ;
Tassi, Elena .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (03) :929-949
[45]   Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers [J].
Fernandes, Ana R. ;
Santos, Ana C. ;
Sanchez-Lopez, Elena ;
Kovacevic, Andjekla B. ;
Espina, Marta ;
Calpena, Ana C. ;
Veiga, Francisco J. ;
Garcia, Maria L. ;
Souto, Eliana B. .
SKIN PHARMACOLOGY AND PHYSIOLOGY, 2018, 31 (02) :59-73
[46]   The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy [J].
Palmieri, Lola-Jade ;
Lavol, J. ;
Dermine, S. ;
Brezault, C. ;
Dhooge, M. ;
Barr, A. ;
Chaussade, S. ;
Coriat, R. .
PHARMACOLOGY & THERAPEUTICS, 2020, 210
[47]   Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments [J].
Lheureux, Stephanie ;
Oza, Amit M. .
EUROPEAN JOURNAL OF CANCER, 2016, 59 :99-108
[48]   Oral complications of targeted cancer therapies: A narrative literature review [J].
Watters, A. L. ;
Epstein, J. B. ;
Agulnik, M. .
ORAL ONCOLOGY, 2011, 47 (06) :441-448
[49]   Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives [J].
Kuwatani, Masaki ;
Sakamoto, Naoya .
CANCERS, 2023, 15 (14)
[50]   A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers [J].
Chia, Brendan Seng Hup ;
Ho, Shaun Zhirui ;
Tan, Hong Qi ;
Chua, Melvin Lee Kiang ;
Tuan, Jeffrey Kit Loong .
CANCERS, 2023, 15 (02)
12345